News
Pegylated Liposomal Doxorubicin Fails to Best Carboplatin-Paclitaxel in Ovarian Cancer
Pegylated Liposomal Doxorubicin Fails to Best Carboplatin-Paclitaxel in Ovarian Cancer
P Wendling
20100614
2010 Jul 14
Elsevier Global Medical News
Pegylated Liposomal Doxorubicin Fails to Best Carboplatin-Paclitaxel in Ovarian Cancer
Elsevier Global Medical News. 2010 Jul 14, P Wendling
CHICAGO (EGMN) - Final results from the Multicenter Italian Trials in Ovarian Cancer-2 show that carboplatin plus pegylated liposomal doxorubicin is no more effective than is the standard first-line chemotherapy of carboplatin plus paclitaxel for advanced ovarian cancer.Median progression-free survival was 16.8 months for carboplatin plus paclitaxel (CP) vs. 19.0 months for carboplatin plus pegylated liposomal doxorubicin (C-PLD) in the final analysis, with 556 events and a median follow-up of 40...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
